Stock Mover of the Day: Nantkwest Inc Just Recorded A Sigfniciant Increase

Stock Mover of the Day: Nantkwest Inc Just Recorded A Sigfniciant Increase

The stock of Nantkwest Inc (NASDAQ:NK) is a huge mover today! About 246,053 shares traded hands or 29.66% up from the average. Nantkwest Inc (NASDAQ:NK) has declined 25.30% since April 14, 2016 and is downtrending. It has underperformed by 29.99% the S&P500.
The move comes after 7 months positive chart setup for the $638.41M company. It was reported on Nov, 16 by Barchart.com. We have $12.63 PT which if reached, will make NASDAQ:NK worth $402.20 million more.

Nantkwest Inc (NASDAQ:NK) Ratings Coverage

Out of 7 analysts covering NantKwest (NASDAQ:NK), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. NantKwest has been the topic of 8 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Piper Jaffray initiated Nantkwest Inc (NASDAQ:NK) rating on Monday, August 24. Piper Jaffray has “Overweight” rating and $38 price target. FBR Capital initiated Nantkwest Inc (NASDAQ:NK) rating on Wednesday, October 28. FBR Capital has “Outperform” rating and $30 price target. The rating was initiated by MLV with “Buy” on Monday, August 24. The stock has “Neutral” rating given by Citigroup on Monday, March 14. The stock has “Buy” rating given by Canaccord Genuity on Tuesday, December 22. The rating was initiated by Raymond James with “Market Perform” on Thursday, June 2. Jefferies initiated Nantkwest Inc (NASDAQ:NK) on Monday, August 24 with “Buy” rating. The stock of Nantkwest Inc (NASDAQ:NK) has “Buy” rating given on Monday, August 24 by Citigroup.

According to Zacks Investment Research, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California.”

More notable recent Nantkwest Inc (NASDAQ:NK) news were published by: Fool.com which released: “Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc.” on October 18, 2016, also Fool.com with their article: “Why NantKwest, Inc.’s Shares Briefly Stumbled Today” published on March 11, 2016, Latimes.com published: “LA billionaire Soon-Shiong gets $148-million payday even as his firm’s stock tanks” on April 28, 2016. More interesting news about Nantkwest Inc (NASDAQ:NK) were released by: Fool.com and their article: “Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals” published on June 28, 2016 as well as Wsj.com‘s news article titled: “NantKwest Gives Biotech Another Big IPO” with publication date: July 28, 2015.

NK Company Profile

NantKwest, Inc., formerly Conkwest, Inc., incorporated on March 12, 2014, is a biotechnology company, which is engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Firm is a clinical-stage immunotherapy firm focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Company’s NK cell platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action, such as direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact; antibody-mediated killing using high-affinity NKs (haNKs), which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and targeted activated killing using target activated Natural Killers (taNKs), which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment